Mergers & Acquisitions - Mergers & Acquisitions, Antibiotics and Infectious diseases

Filter

Popular Filters

FTC puts conditions on Sun Pharma’s proposed acquisition of Ranbaxy

FTC puts conditions on Sun Pharma’s proposed acquisition of Ranbaxy

01-02-2015

Indian drugmakers Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories have agreed to divest Ranbaxy’s…

Antibiotics and Infectious diseasesGenericsIndiaLegalMergers & AcquisitionsMinocyclineRanbaxy LaboratoriesSun Pharmaceutical IndustriesTorrent PharmaceuticalsUSA

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

19-01-2015

Motif Biosciences, a partner of life science business developer Amphion Innovations, has entered into…

Amphion InnovationsAntibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsMotif BiosciencesMRSA antibioticUSA

NetScientific invests in PDS Biotechnology

NetScientific invests in PDS Biotechnology

15-12-2014

UK-based life sciences investor NetScientific has made an undisclosed investment in privately-held US…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsNetScientificOncologyPDS BiotechnologyUK

Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion

08-12-2014

Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

Actavis to acquire Durata Therapeutics for $675 million

Actavis to acquire Durata Therapeutics for $675 million

06-10-2014

In a move that takes it further out of its main generics business, Ireland-headquartered Actavis has…

ActavisAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsIrelandMergers & AcquisitionsPharmaceutical

FTC approves final order on Akorn divestment in bid for VersaPharm

FTC approves final order on Akorn divestment in bid for VersaPharm

21-09-2014

Following a public comment period, the US Federal Trade Commission has approved a final order settling…

AkornAntibiotics and Infectious diseasesGenericsLegalMergers & AcquisitionsRifampinUSAVersaPharm

FTC puts conditions on Akorn’s proposed acquisition of VersaPharm

FTC puts conditions on Akorn’s proposed acquisition of VersaPharm

05-08-2014

The US Federal Trade Commission revealed yesterday that US generics drugmaker Akorn has agreed to sell…

AkornAntibiotics and Infectious diseasesClinical researchGeneric injectable tuberculosisGenericsMergers & AcquisitionsRegulationRifampinUSAVersaPharm

ANI Pharma acquires Vancocin assets from Shire

ANI Pharma acquires Vancocin assets from Shire

02-08-2014

US generic drugmaker ANI Pharmaceuticals says it has acquired the US rights for the antibiotic Vancocin…

ANI PharmaceuticalsAntibiotics and Infectious diseasesEli Lilly and CompanyGenericsGlycopeptide antibioticsIrelandMergers & AcquisitionsNew DrugShireUSAVancocinVancomycin HCl

Transcept and Paratek join forces in reverse takeover

Transcept and Paratek join forces in reverse takeover

01-07-2014

US pharma company Transcept Pharmaceuticals and privately-held biopharmaceutical company Paratek Pharmaceuticals…

Antibiotics and Infectious diseasesMergers & AcquisitionsParatek PharmaceuticalsPharmaceuticalTranscept PharmaUSA

Evotec to acquire Euprotec to establish an anti-infectives platform

Evotec to acquire Euprotec to establish an anti-infectives platform

29-05-2014

Germany’s Evotec says it has acquired all the shares in Euprotec Ltd, a UK-based specialist contract…

Anti-infective drug discovery servicesAntibiotics and Infectious diseasesBusiness FinanceDiseaseEvotecHealth Medical PharmaMergers & AcquisitionsPharmaceuticalRecognised leader

Debiopharm to acquire Affinium's antibiotic clinical assets and platform

11-02-2014

Swiss drug developer Debiopharm Group has entered into an agreement to acquire Canadian venture capital…

Affinium PharmaceuticalsAFN-1720Antibiotics and Infectious diseasesDebiopharmMergers & AcquisitionsPharmaceutical

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

06-01-2014

Japanese drug major Astellas Pharma has entered into a strategic partnership with ClearPath Development…

Antibiotics and Infectious diseasesAstellas PharmaClearPath DevelopmentLicensingMergers & AcquisitionsMymetics CorpOtsukaPharmaceuticalRSV CorpTaiho Pharmaceutical

The Medicines Company acquires antibiotics maker Rempex Pharma

04-12-2013

USA-based The Medicines Company has acquired Rempex Pharmaceuticals, a company with multiple potential…

Antibiotics and Infectious diseasesMergers & AcquisitionsPharmaceuticalRempex PharmaceuticalsThe Medicines Company

Cubist Pharma signs two acquisition deals in one day

31-07-2013

In what must have been a busy day for US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) announced not…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMergers & AcquisitionsOptimer PharmaceuticalsPharmaceuticaltedizolidTrius Therapeutics

Terms amended in Bellus' acquisition of Thallion

23-07-2013

Canada-based drugmaker Bellus Health (TSX: BLU) has amended its agreement to acquire fellow Canadian…

Antibiotics and Infectious diseasesBellus HealthBiotechnologyMergers & AcquisitionsNorth AmericaShigamabsThallion Pharmaceuticals

Briefs: Boehringer files Pradaxa for DVT and PE; Astellas' Mycamine pediatric approval; Simcere divests Boda

25-06-2013

Family-owned German drug major Boehringer Ingelheim has submitted an application to the European Medicines…

Antibiotics and Infectious diseasesAstellas PharmaBoehringer IngelheimCardio-vascularEuropeJilin BodaMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationSimcere PharmaceuticalYidashen

Grifols gains global rights to Aradigm's Pulmaquin

23-05-2013

Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's…

Antibiotics and Infectious diseasesAradigmCiprofloxacinGrifolsLicensingMergers & AcquisitionsPharmaceuticalPulmaquinRespiratory and Pulmonary

Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal

21-05-2013

Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk…

Antibiotics and Infectious diseasesGenericsMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalXellia Pharmaceuticals

DCC Healthcare acquires generic drugmaker Kent Pharma

24-12-2012

Dublin, Ireland-based sales, marketing, distribution and business support services group DCC, says that…

Antibiotics and Infectious diseasesDCC HealthcareGenericsKent PharmaceuticalMergers & Acquisitions

Synthetic Biologics to acquire clinical-stage C. diff infectious disease program

12-11-2012

USA-based Synthetic Biologics (NYSE: SYN), a developer of synthetic biologics and innovative medicines…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsPrev AbRSYN-004Synthetic Biologics

MicuRx joins forces with VC for next-generation antibiotic for China

24-10-2012

MicuRx Pharmaceuticals, a privately-held US biopharmaceutical company developing next-generation antibiotics,…

Antibiotics and Infectious diseasesAsia-PacificMergers & AcquisitionsMicuRx PharmaceuticalsMRX-IPharmaceuticalResearchShanghai MengKe Pharma

Forest acquires rights to Nabriva antibacterial and option to buy firm

04-06-2012

US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

News briefs: GlaxoSmithKline and Bayer

24-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx

01-05-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generics companies, said…

Antibiotics and Infectious diseasesDoryxGenericsLegalMergers & AcquisitionsMylan LaboratoriesNeurologicalNorth AmericaNuvigilPatentsPharmaceuticalTeva Pharmaceutical IndustriesWarner Chilcott

Back to top